Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a ...

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...

In addition, Olema has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less underwriting discounts and ...

Olema Pharmaceuticals stock surged 197% after Roche reported positive trial results for a similar breast cancer drug.

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies ...

OLMA stock surged 197% after Roche’s SERD breakthrough, signaling investor conviction in the future of ER-positive breast ...

Olema Pharmaceuticals (OLMA) surges after Roche's breast cancer data, but caution is urged as key clinical results are ...

Galmed reported new data showing that its Aramchol–Stivarga–Metformin combination improved tumor cell killing in GI cancer ...

Key Takeaways Abbott Laboratories has agreed to acquire Exact Sciences Corp. in a deal worth $21 billion, paying shareholders $105 per share.Exact Sciences makes a variety of cancer screening tests, ...